newsfilter
← Latest News
GlobeNewswire·

Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

  • Immutep Limited received US patent 12,788,796 from the USPTO for combined preparations to treat cancer or infection.
  • The patent covers eftilagimod alfa in combination with PD-1 pathway inhibitors, specifically BMS-936559, durvalumab, atezolizumab, and avelumab.
  • Immutep now holds five US patents within this family, following grants in December 2020, March 2021, June 2023, July 2026, and this latest grant.
  • The patent expires on 23 March 2038, including an 806-day patent term adjustment.
  • Immutep has filed a continuation application to pursue additional embodiments of the invention.
  • CEO Marc Voigt stated the grant strengthens intellectual property protection for efti, supporting future development and partnering opportunities.
  • Efti is a proprietary soluble LAG-3 protein with Fast Track designation for first-line head and neck squamous cell carcinoma and non-small cell lung cancer, plus Orphan Drug Designation for soft tissue sarcoma.
  • Immutep is a clinical-stage biotechnology company focused on LAG-3 therapeutics for cancer and autoimmune diseases.
Company
Immutep Limited
Keywords
Nasdaq:IMMP, Immutep Limited